ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0570

Treatment for CKD: A Systematic Literature Review and Population Comparison

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

  • Garcia Sanchez, Juan Jose, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
  • Thompson, Juliette C., Visible Analytics, Oxford, United Kingdom
  • Scott, David Alexander, Visible Analytics, Oxford, United Kingdom
  • Rao, Naveen, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
  • SOrstadius, Elisabeth, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
  • James, Glen, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
  • Nolan, Stephen, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
  • Wittbrodt, Eric T., BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, United States
  • Abdul Sultan, Alyshah, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
  • Stefansson, Bergur V., BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
  • Jackson, Dan, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
  • Hawkins, Neil S., Visible Analytics, Oxford, United Kingdom
  • Abrams, Keith R., Visible Analytics, Oxford, United Kingdom
Background

DAPA-CKD is the first renal outcomes trial assessing the efficacy and safety of a sodium–glucose cotransporter-2 inhibitor, dapagliflozin, vs placebo, added to standard of care in patients with chronic kidney disease (CKD) with/without type 2 diabetes (T2D). Several other agents have been or are currently under investigation for their effect on renal and cardiovascular outcomes in CKD; however, comparisons of efficacy are challenging, due to differences in study design, duration, patients and endpoint definitions. We conducted a systematic literature review of randomized controlled trials (RCTs) in CKD, with the aim of assessing inter-study comparability.

Methods

Searches of MEDLINE, Embase, the Cochrane Central Register of Controlled Trials and grey literature sources were conducted to identify phase 3–4 RCTs of adults (≥18 years) with albuminuric CKD with/without T2D, published in English between 1990 and March 25, 2020. Studies of ≥12 weeks duration that reported clinical outcomes, adverse events, quality of life or patient-reported outcomes for pharmacologic CKD treatments were eligible for inclusion.

Results

Preliminarily, 13,451 unique citations were identified, and 204 full-text manuscripts were included after abstract screening (Figure). Data from 81 RCTs were included: 24, 39 and 18 in patients with CKD with/without T2D, CKD with T2D and CKD without T2D, respectively.

Conclusion

As anticipated, differences in the inclusion of patients with/without T2D between studies make comparisons difficult. Future work will compare additional relevant study characteristics, with further insights available in October 2020.

Figure: PRISMA diagram

Funding

  • Commercial Support